Search

Sitting Down With…John Doench, Associate Director, Genetic Perturbation Platform, Broad Institute, Cambridge, MA, USA.

There is an assumption that doctors and business don’t mix. But I believe physicians are ideally placed to bring new clinical innovations from a bright idea to a brand new product.

The Ebola epidemic spurred a tremendous amount of R&D in search of vaccines and treatments – and yet it was a relatively low impact global emergency compared with malaria.

Open innovation is more than just the latest pharma industry buzzword. Done right, it can help overcome funding challenges and accelerate discovery across the board.

A gene therapy approach for hemophilia-causing Factor VII deficiency shows early promise

What do we know so far?

How can we get drugs to the liver to treat its dysfunction, without making it worse?

What can Drosophila eyes tell us about the origins of cancer?

French physicists have developed a thermal imaging technique that maps heat across a single cell

Researchers can control aggression in mice by turning on specific neurons – but what are the implications for human rage?